Press Releases

Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today the Taiwan Food and Drug Administration and Ministry of Food and Drug Safety in South Korea have granted fast-tracked approval process to Nefecon®. Nefecon is our lead product in the renal disease portfolio as a first-in-disease treatme

Diamyd Medical announced today that the U.S. Food and Drug Administration  has lifted the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd in individuals recently diagnosed with type 1 diabetes. Following the decision from the FDA, DIAGNODE-3 is approved to start in the US. "This is a significant milestone for Diamyd Medical and more importantly, for

India is set for record growth in 2023 after pharma manufacturers report surging international partnering at CPHI Frankfurt. Contract Manufacturing organisations (CMO) appear to be the biggest beneficiaries of new contracts, closely followed by API manufacturers in the country. In fact, for the first time Indian API manufacturing has surpassed the quality scores of even Europe’s leading API hub – Italy – in the CPHI Annual Survey. Last week’s CPHI Frankfurt s

Cosmetic Physician Partners Inc is pleased to announce its official launch in the US with the closing of its 10th medical aesthetics clinic. Led by industry experts Dr. A. Jay Burns, Dr. Joel L. Cohen, Matt and Kathy Taranto and Dan Schacter, CPP is a partnership designed to provide physician owners with an alternative to private equity. Built from the ground up to support owners, CPP provides superior financial upside to its partners, an array of deep expertise through centralized services&n

Ascletis Pharma Inc.announces today that the U.S. Food and Drug Administration has approved the Investigational New Drug application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19. U.S. FDA has approved to study safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects co-dosed with 100 mg ritonavir tablets. Both ASC11 and ritonavir tablets are manufactured by Ascletis. The Phase I clinical trial

Vieworks, a leading digital x-ray imaging solution provider based in South Korea, will be exhibiting its complete lineup of DR flat panel detectors and dynamic FPDs at RSNA 2022 from November 27th to November 30th.Celebrating the FDA-approval of VIVIX-S F series, the latest and most advanced line of Vieworks' FPDs, Vieworks will highlight its fully commercialized 3rd generation FPDs (VIVIX-S V series and VIVIX-S F series). Dynamic FPDs employing both a-Si and IGZO panel technology and mam

Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced today that a Top 10 pharmaceutical company is leveraging medication pooling, an advanced inventory management strategy available through Calyx IRT to improve drug distribution efficiencies and reduce drug wastage in an ongoing, global clinical development program. The Top 10 pharma company is benefitting from Calyx's proven solution wh

Inspira Technologies OXY B.H.N. Ltd.a groundbreaking respiratory support technology company, announced today that it has signed an exclusive distribution agreement for the HYLA Blood Sensor with Innovimed Sp. z o.o a company specializing in the commercialization of medical products in Europe, Middle East and Africa. The Company recently announced that it is preparing for a clinical study of the HYLA Blood Sensor to be performed alongside patients undergoing cardio-p

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the World Antiviral Congress 2022, which will be held in San Diego, Calif., November 28 - December 1, 2022. A copy of the presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting inform

Sinoveda is a revolutionary health-science brand that is changing the way consumers can approach health and wellness. As one of seven Canadian companies recognized to have "disruptive technologies," Sinoveda has established itself as a health brand that truly understands how to bring science and nature together. Founders Dr. Yun Tam and Dr. Nuzhat Tam-Zaman are both professional colleagues and spouses. They were raised in Hong Kong and Bangladesh and received extensive education in